The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Quetiapine Rowex 50 mg Prolonged-release tablets

50 milligram(s) Prolonged-release tablet

Rowex LtdPA0711/231/001

Main Information

Trade NameQuetiapine Rowex 50 mg Prolonged-release tablets
Active SubstancesQuetiapine
Strength50 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderRowex Ltd
Licence NumberPA0711/231/001

Group Information

ATC CodeN05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH04 quetiapine


Licence Issued13/09/2013
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceQuetiapine Rowex 50 mg Prolonged-release Tablets is a registration name only. The MAH shall not market the product using this registration name. The MAH shall change the name to an invented name by way of variation prior to marketing the product in Ireland.
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0019-023-024
Interchangeable List DocumentPDF of Interchangeable List
« Back